

Contents

Abbreviations used	iii
Grading of recommendations	iv
List of tables and boxes	iv
Contents	v
Executive summary of recommendations	x
1 Purpose and scope	1
2 Identification and assessment of the evidence	1
3 Introduction	2
4 Summary, including changes to existing guidance	2
5 What is combined hormonal contraception?	4
5.1 Hormonal content of combined hormonal contraception	4
5.1.1 Estrogens	4
5.1.2 Progestogens	4
5.2 What methods of CHC are available in the UK?	5
5.3 How does CHC work?	5
6 How is CHC used?	5
6.1 Standard CHC regimens	6
6.1.1 Combined oral contraception	6
6.1.2 Combined transdermal patch	6
6.1.3 Combined vaginal ring	6
6.2 Tailored CHC regimens	6
6.2.1 Suggested tailored CHC regimens	7
6.2.2 Contraceptive effectiveness of tailored CHC regimens	7
6.2.3 Safety of tailored CHC regimens	8
6.2.4 Bleeding patterns with extended CHC regimens	9
6.2.5 Tailored CHC regimens and symptoms associated with the HFI	9
6.2.6 Return to fertility after use of extended CHC regimens	10
6.2.7 Acceptability of tailored CHC regimens	10
6.2.8 Offering tailored CHC regimens	11



6.3	When can CHC be started?	11
6.3.1	Starting CHC at the beginning of a natural menstrual cycle	12
6.3.2	Quick starting CHC	12
6.3.3	Summary of advice for starting CHC	13
6.3.4	Switching to CHC from other contraceptive methods	14
7	How effective is CHC?	16
7.1	Contraceptive effectiveness of CHC	16
7.2	What can affect contraceptive effectiveness of CHC?	18
7.2.1	Is contraceptive effectiveness of CHC affected by obesity/weight?	18
7.2.2	Is contraceptive effectiveness of CHC affected by bariatric surgery?	18
7.2.3	What drug interactions are important to consider in relation to CHC?	19
7.2.4	Severe diarrhoea or vomiting	21
8	Incorrect use of CHC	21
8.1	Combined oral contraception	21
8.2	Combined transdermal patch	22
8.3	Combined vaginal ring	22
9	Non-contraceptive health benefits associated with CHC use	23
9.1	Heavy menstrual bleeding	23
9.2	Menstrual pain	23
9.3	Acne	24
9.4	Premenstrual symptoms	24
9.4.1	EE/DRSP COC for management of premenstrual symptoms	24
9.4.2	Other COC for management of premenstrual symptoms	24
9.4.3	Extended COC regimens for management of premenstrual symptoms	24
9.5	Vasomotor symptoms	25
9.6	Bone health	25
9.7	Endometriosis	25
9.8	Polycystic ovary syndrome	26
9.9	Effect of CHC use on cancer risk and mortality	27
9.9.1	Endometrial cancer	27

9.9.2	Ovarian cancer	28
9.9.3	Colorectal cancer	28
9.9.4	Mortality	28
10	Health risks associated with CHC use	29
10.1	Venous thromboembolism (VTE) (including deep vein thrombosis and pulmonary embolism)	29
10.1.1	Effect of progestogen type on VTE risk	29
10.1.2	Effect of dose of EE on VTE risk	30
10.1.3	Effect of estrogen type on VTE risk	30
10.1.4	Effect of route of administration on VTE risk	31
10.1.5	Women with inherited thrombophilias	31
10.2	Arterial thromboembolic disease	32
10.2.1	CHC use and risk of myocardial infarction	33
10.2.2	CHC use and risk of ischaemic stroke	33
10.2.3	Estrogen dose and risk of ATE	33
10.2.4	Progestogen type and risk of ATE	34
10.2.5	Estrogen type and risk of ATE	34
10.2.6	Route of administration and risk of ATE	34
10.2.7	Additional risk factors for ATE	34
10.3	CHC use and risk of haemorrhagic stroke	35
10.4	Breast cancer	35
10.4.1	CHC use and risk of breast cancer	35
10.4.2	Family history of breast cancer	36
10.4.3	Genetic mutations relevant to breast cancer risk	36
10.5	Cervical cancer	37
11	Side effects associated with CHC use	37
11.1	CHC and headache	38
11.2	Unscheduled bleeding with CHC (breakthrough bleeding)	38
11.2.1	Differences in bleeding pattern between routes of CHC administration	38
11.2.2	Differences in bleeding patterns between formulations of oral contraceptives	39
11.2.3	Differences in bleeding patterns between CHC regimens	40



11.3	Mood	40
11.4	Weight gain	42
11.5	Effect on libido	42
11.6	Return to fertility	42
12	What should be done in an initial CHC consultation?	43
12.1	Assessment of suitability of CHC for an individual woman	44
12.1.1	Assessment of medical eligibility for CHC	44
12.1.2	Assessment of factors that could affect contraceptive effectiveness	46
12.1.3	Women for whom CHC is unsuitable	47
12.2	Choosing a method of contraception	47
12.3	Choosing type and formulation of CHC	47
12.4	Choosing a regimen for CHC use	47
12.5	Other important supporting information	48
12.6	Duration of CHC prescription	49
12.6.1	Combined oral contraception	49
12.6.2	Combined transdermal patch	50
12.6.3	Combined vaginal ring	50
13	What follow-up is required for women continuing with use of CHC?	50
13.1	What follow-up arrangements are appropriate?	50
13.1.1	What should be done at CHC follow-up?	50
13.2	Online and remote provision of CHC	51
14	What specific advice is required for women using CHC?	52
14.1	CHC use during travel	52
14.1.1	VTE risk during travel	52
14.1.2	Adherence to CHC when crossing time zones	52
14.2	CHC use at high altitude	52
14.3	Surgery/periods of immobilisation	53
15	What recommendations are there regarding stopping CHC?	53
15.1	How long can women use CHC?	53
15.1.1	Use of CHC by women aged over 40 years	53
15.1.2	Duration of CHC use	54

15.2 Switching to another method of contraception	54
15.3 Planning pregnancy	54
15.3.1 Return of fertility	54
15.3.2 Preconception care	54
15.3.3 Unplanned pregnancy during CHC use	54
16 Use of CHC in the perimenopause	55
16.1 Use of CHC as an alternative to HRT	55
16.2 Transition to HRT	55
Recommendations for future research	55
Considerations for implementation of this guideline	55
Useful links	55
References	56
Appendices	83
Appendix 1: FSRH Clinical Guideline Development Process	83
Appendix 2: Sections of UKMEC that contain conditions that are UKMEC 3 or 4 for use of combined hormonal contraception	88
Questions for continuing professional development	91
Auditable outcomes	92
Comments and feedback on published guideline	93
Correction notice	94

Information box

Title	Combined Hormonal Contraception
Author/Publisher	Faculty of Sexual & Reproductive Healthcare
Publication date	January 2019 (amended November 2020)
Superseded document	Combined Hormonal Contraception 2011
Review date	January 2024
Available online	https://www.fsrh.org/standards-and-guidance/documents/combined-hormonal-contraception/